Piper Sandler Maintains Overweight on Gossamer Bio, Lowers Price Target to $96
Benzinga Newsdesk 11 hours ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst Yasmeen Rahimi maintains Gossamer Bio (NASDAQ:GOSS) with a Overweight and lowers the price target from $120 to $96.
Piper Sandler analyst Yasmeen Rahimi maintains Gossamer Bio (NASDAQ:GOSS) with a Overweight and lowers the price target from $120 to $96.